SUBSCRIBERS

Biolidics launches IPO to raise S$6.1m

Wed, Dec 12, 2018 - 5:50 AM

Lee Meixianleemx@sph.com.sg@LeeMeixianBT

Ivan Lew, executive director and CEO of Biolidics, with the company's patented technology that can separate cancer cells from blood to test for the presence of cancer.

Singapore

MEDICAL technology company Biolidics on Tuesday launched an initial public offering (IPO) of 27.5 million new shares at S$0.28 each. The placement is in conjunction with its proposed listing on the Catalist board on Dec 19.

The shares will be placed out to retail and...

To continue reading

for full content

if you are a subscriber

Get our introductory offer at only

$0 .99*/month

Cancel anytime

*$0.99/month for first 3 months

$29.90/month for the next 9 months

Need help?

CALL +65 6388 3838 EMAIL btocs@sph.com.sg

OPERATING HOURS (+8 GMT) MON-FRI: 8:30AM-5:30PM

Register to read this article. Log in if you are already a subscriber. Register to read this article. Log in if you are already a subscriber. Please log in or subscribe to continue reading.